Serious menstrual bleeding associated with use of TNF alpha blocker: two cases.
Menstrual disorders associated with the use of TNF alpha blocker have been rarely reported. Herein, we reported two cases aged 31 and 41, presenting with excessive menstrual bleeding occured after adalimumab administration which was subsequently discontinued.
Bes
Cemal
C
Department of Rheumatology, Abant Izzet Baysal University Medical School, Bolu, Turkey. cemalbes@hotmail.com
Soy
Mehmet
M
D000068879:Adalimumab; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004412:Dysmenorrhea / Q000139:chemically induced* / Q000175:diagnosis; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D004958:Estradiol; D000068879:Adalimumab